Preview Newsletter

XARELTO Media Monitoring – Week of 10-2-15

Plaintiff Attorney Blog Press Releases

Xarelto Lawsuit Update: Number of Internal Bleeding Lawsuits Continues to Rise
Sep 25, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports today on the rising number of internal bleeding lawsuits that are being filed in the Xarelto federal multidistrict litigation. As of August 17, 2015, a total of 1,231 lawsuits have been filed in the Xarelto MDL in the Eastern District of Louisiana. These numbers show a huge increase in the total number of lawsuits filed, as of July there were only 805 lawsuits consolidated in the MDL and back in June there were only 500.
Xarelto Lawsuit News: Bellwether Trials, Wrongful Death Allegations
Sep 28, 2015 | Bio-Medicine
By Onder, Shelton, OLeary & Peterson, LLC

A national personal injury law firm involved in Xarelto lawsuits against Janssen Research and Development and Bayer Healthcare Pharmaceuticals provides a news update on the status of the pending litigation.* According to the attorneys, the number of Xarelto lawsuits currently stands at nearly 1,700 separate actions which have been filed nationwide since the MDL was consolidated in December of last year.
Xarelto Lawsuit Update: Statute of Limitations Expiring on Potential Lawsuits
Sep 29, 2015 | Digital Journal
By Marc Goldich

BloodThinnerHelp.com reports today on the statutes of limitations for Xarelto lawsuits and how they vary over different states. The statutes of limitations are a set of laws on the books that dictate the amount of time that a plaintiff has to bring a lawsuit forward. The time period usually begins when the event occurred or should have been discovered. If the plaintiff does not bring a lawsuit forward within this time period, they will be permanently barred from recouping damages. It is very important to file a Xarelto lawsuit as soon as you can to make sure that the statute of limitations does not expire on your case.
Xarelto Lawsuit News: New Xarelto Settlement Update
Sep 29, 2015 | WDRB.com
By Marc Goldich

BloodThinnerHelp.com reports today on the latest news about Xarelto lawsuit settlements. Although at this point in time no settlements have been made, initial trial dates have been announced and the litigation is moving forward.
Xarelto MDL Lawsuits Are Different From Class Actions
Oct 1, 2015 | KUSI News
By Marc Goldich

BloodThinnerHelp.com reports today on the difference between the current Xarelto litigation and class action lawsuits. Although sometimes confused or used interchangeably, multidistrict litigation and class action lawsuits are very different. A large number of the current cases filed against the manufacturers of Xarelto, more than 1,200, are consolidated into a federal multidistrict litigation in the United States District Court for the Eastern District of Louisiana. Consolidating cases into an MDL still allows these cases to be tried separately and settlements to be decided individually. This is especially important because the circumstances of the cases filed and the injuries the plaintiffs suffered all greatly vary.
Xarelto MDL Lawsuits Are Different From Class Actions
Oct 1, 2015 | KCEN-TV
By Marc Goldich

BloodThinnerHelp.com reports today on the difference between the current Xarelto litigation and class action lawsuits. Although sometimes confused or used interchangeably, multidistrict litigation and class action lawsuits are very different. A large number of the current cases filed against the manufacturers of Xarelto, more than 1,200, are consolidated into a federal multidistrict litigation in the United States District Court for the Eastern District of Louisiana. Consolidating cases into an MDL still allows these cases to be tried separately and settlements to be decided individually. This is especially important because the circumstances of the cases filed and the injuries the plaintiffs suffered all greatly vary.

Plaintiff Attorney Blog Posts

Florida Widow Claims Xarelto Injury Caused Husband’s Death
Sep 25, 2015 | Top Class Actions
By Tamara Burns

A Florida widow has filed a dangerous drug lawsuit against the maker of Xarelto, claiming the blood thinning drug caused the wrongful death of her husband. Plaintiff Betty H., the widow of Ronald H., filed the Xarelto lawsuit against Janssen Pharmaceuticals, its parent company Johnson & Johnson and affiliated companies over the alleged injury caused by her late husband Ronald’s Xarelto usage.
Japan Expands Indication For Blood Thinner Xarelto
Sep 28, 2015 | Righting Injustice
By Jennifer Walker-Journey

The controversial blood thinner Xarelto has been granted clearance by Japanese drug regulators for expansion of the drug’s usage to include the treatment and secondary prevention of pulmonary thromboembolism (PE) and deep vein thrombosis (DVT).
Xarelto Bellwether Trials Set to Begin in 2017
Sep 29, 2015 | Childress, Schlueter & Smith

A series of Xarelto bellwether trials may begin as soon as February 2017, according to a Case Management Order issued on September 17 by the U.S. District Court, Easter District of Louisiana. The cases are part of a federal multidistrict litigation (MDL) established in December 2014 to consolidate product liability complaints filed in federal court involving bleeding problems with the anticoagulant drug Xarelto. Early bellwether trials are commonly conducted to further the efficient progress of litigation.
Xarelto: Higher Risk Same Reward?
Sep 29, 2015 | Lopez McHugh LLP

Over 1,200 Xarelto lawsuits are pending in a multidistrict litigation in the U.S. District Court for the Eastern District of Louisiana. Xarelto plaintiffs allege that the anticoagulant drug’s manufacturers, including Bayer HealthCare Pharmaceuticals and Johnson & Johnson’s Janssen Pharmaceutical, did not provide patients and doctors with adequate warning about Xarelto’s severe bleeding risks.
Xarelto Lawsuit Update: New Pre-Trial Orders Issued in MDL
Sep 30, 2015 | The Legal Herald
By Marc Goldich

Two new pretrial orders were issued in late September for the Xarelto MDL. If you or a loved one have been injured by Xarelto, contact us immediately. BloodThinnerHelp.com reports today on two new orders issued for the Xarelto multidistrict litigation. On September 17, 2015, the United States District Court in the Eastern District of Louisiana, where the MDL is consolidated, issued the second Case Management Order, the full text of which can be found here. The court also issued Pretrial Order 15A, which was an order in regards to the preservation of emails, text messages, and instant messages. Pretrial Order 21 was also issued which established document production protocol for the litigation. More information on the two Pretrial Orders can be found here.
Fair Rate Funding Now Offering Lawsuit Funding for Xarelto Lawsuits
Sep 30, 2015 | Fair Rate Funding

Xarelto (rivaroxaban) is an anticoagulant (blood thinner) that prevents the formation of blood clots and is marketed by Johnson & Johnson and manufactured by Bayer. Its primary use is to reduce the risk of blood clots in the legs and lungs of people who recently had a hip or knee replacement surgery. It is also used to treat and reduce the risk of deep vein thrombosis, pulmonary embolisms and strokes.
Plaintiffs Claim Xarelto Is Unsafe and Improperly Marketed
Sep 30, 2015 | LawyersandSettlements.com
By Gordon Gibb

A Xarelto Lawsuit filed this past March raises a lot of the same questions other plaintiffs have been raising with regard to Xarelto Bleeding complications that can’t be stopped as easily as similar bleedouts associated with use of the much older Coumadin (warfarin).
Xarelto Lawsuit (YouTube Video)
Oct 1, 2015 | YouTube
By Ben Jones

The video only features text that discusses the alleged dangers of Xarelto and prompts individuals to contact the law firm for a free consultation. Video: https://www.youtube.com/watch?v=6_OAUlRxl_0
Have You Been Harmed By Xarelto? Here’s How We Can Help
Oct 1, 2015 | Baron Budd

Xarelto, the brand name of the drug rivaroxaban, is a blood thinner marketed as a much more convenient alternative to older medications such as warfarin, which has been in use since the 1950s. Manufactured by Johnson & Johnson subsidiary Janssen Pharmaceuticals, Xarelto has been linked to several serious – and often fatal – health problems caused by uncontrolled bleeding. As a result, people across the country are filing Xarelto lawsuits.
Xarelto Lawsuit Filings Keep Coming
Oct 1, 2015 | Bernstein Liebhard LLP
By Sandy Liebhard

Xarelto lawsuits continue to pile up in courts around the country. Most recently, 12 plaintiffs filed suit in Louisiana federal court accusing Johnson & Johnson and Bayer Corp. of downplaying the risk of internal hemorrhaging associated with the new-generation blood thinner.
Xarelto Bleeding Lawsuit Alleges Ohio Man Bled to Death
Oct 2, 2015 | Top Class Actions
By Ashley Vanover

The controversial blood thinning drug Xarelto has been named in yet another lawsuit – this time following the death of an Ohio resident who was prescribed the medication in July 2013. Plaintiff Judy C., filing on behalf of her deceased spouse, commenced her Xarelto wrongful death lawsuit on Sept. 15 in Louisiana federal court, home of the ongoing Xarelto MDL to address the alleged widespread injuries caused by the new generation anticoagulant.
Son Blames Xarelto for Father’s Death, Seeks Punitive Damages
Oct 2, 2015 | The Legal Examiner
By Eric T. Chaffin

In December 2014, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated all federal Xarelto lawsuits into one court in the Eastern District of Louisiana before the Honorable Judge Fallon. Currently, about 400 cases are pending there.One of the cases recently filed involves a plaintiff who claims the anticoagulant blood caused internal bleeding that led to the death of his father

Plaintiff Attorney Blog Press Releases

Xarelto Lawsuit Update: Number of Internal Bleeding Lawsuits Continues to Rise

Sep 25, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports today on the rising number of internal bleeding lawsuits that are being filed in the Xarelto federal multidistrict litigation. As of August 17, 2015, a total of 1,231 lawsuits have been filed in the Xarelto MDL in the Eastern District of Louisiana. These numbers show a huge increase in the total number of lawsuits filed, as of July there were only 805 lawsuits consolidated in the MDL and back in June there were only 500. For more detailed information about the Xarelto lawsuits, click here.
The MDL is presided over by Judge Eldon Fallon and the Eastern District of Louisiana is located in the city of New Orleans. A motion was made to form the MDL because there was a rising number of lawsuits that all made similar allegations against the same defendants, the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson. By consolidating these cases into an MDL, the entire litigation process is streamlined and will move faster for everyone involved. Forming an MDL also saves on judicial resources and speeds up the settlement process if there is one.
In addition to the MDL, there is also a Mass Tort Group in Philadelphia where about 400 Xarelto lawsuits are currently consolidated. The number of lawsuits consolidate in the Mass Tort Group and the MDL continue to rise.
Lawsuits Allege Xarelto Linked to Serious Side Effects:
Xarelto was released onto the United States market after being approved by the Food and Drug Administration, FDA, in 2011. Xarelto was initially approved to treat patients who suffered from atrial fibrillation, deep vein thrombosis, and for patients who had recently undergone a hip or knee replacement surgery. Since its release, several studies have linked Xarelto to cause severe internal bleeding which can lead to serious injuries and even death. This internal bleeding is serious because Xarelto does not have an antidote to counteract its anticoagulant effects. If a patient is taking the traditional blood thinner Warfarin and experiences an internal bleed, doctors can administer Vitamin K and the patient’s blood will clot. If a patient is taking Xarelto and experiences an internal bleed, there is no available medication to stop the bleeding. Many patients taking Xarelto have been seriously injured in this way and have even died.
Many of the Xarelto lawsuits filed allege that Xarelto’s manufacturers were aware of the serious risks associated with the drug yet put the blood thinner to market anyway. The lawsuits also allege that the manufacturers deliberately concealed this information from doctors and patients, claiming in advertisements that Xarelto was a safe drug.
“If the defendants did indeed know about Xarelto’s dangers and deliberately concealed that information, they deserve to be brought to justice.” Xarelto attorney Marc Goldich said, “If you or a loved one have been harmed by Xarelto, contact us immediately.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.digitaljournal.com/pr/2686725

Read more: http://www.digitaljournal.com/pr/2686725#ixzz3n3EtolwF

Return to headline | Return to top
Xarelto Lawsuit News: Bellwether Trials, Wrongful Death Allegations

Sep 28, 2015 | Bio-Medicine

By Onder, Shelton, OLeary & Peterson, LLC

A national personal injury law firm involved in Xarelto lawsuitsagainst Janssen Research and Development and Bayer Healthcare Pharmaceuticals provides a news update on the status of the pending litigation.* According to the attorneys, the number of Xarelto lawsuits currently stands at nearly 1,700 separate actions which have been filed nationwide since the MDL was consolidated in December of last year.
Last week, on September 17, a monthly status conference was held. Topics addressed at the Status Conference included the determination of bellwether cases, according to court documents. Bellwether trials, which are used as representative case studies, help determine how the entire litigation will be resolved. Bellwether trials are scheduled to take place in less than a year, in August of 2016, according to court documents. At the suggestion of the court, two bellwether trials will take place in the Eastern District of Louisiana, one in the Southern District of Texas, and another in the Southern District of Mississippi, according to court documents.
“While the attorneys working on this case are involved in discovery and working out the logistics of how this very complex litigation will move forward, new cases are being added all the time,” explained a representative of the Onder Law Firm. “The cases are coming from people all around the country. As attorneys representing numerous plaintiffs in this case, it is our goal to stayed involved in the minute details as the litigation moves forward so that our clients can focus on rebuilding their lives. We take our job very seriously.”
While the plaintiffs are diverse, the cases each allege that Xarelto caused a patient to suffer from severe internal bleeding or hemorrhagic stroke, according to court documents. Xarelto is used to lower the risk of stroke and blood clot formation in patients who suffer from or are at risk for atrial fibrilation, deep vein thrombosis, and pulmonary embolism. Xarelto has proved to be effective at preventing the blood from clotting, but as such poses a risk for serious bleeding. All anti-coagulant drugs pose this risk, but Xarelto lawsuits assert that because there is no known antidote to Xarelto bleeding events, the drug is less safe than other blood thinners, having causes serious internal bleeding and bleeding deaths, according to court documents. Xarelto lawsuits also allege that warning information contained in the drug's label is inadequate for these dangers, failing to convey the alleged serious and deadly side effects of Xarelto, according to court documents.
Xarelto lawyers representing clients nationwide for the Onder Law Firm are now accepting claims from individuals and families of individuals who suffered from severe internal bleeding or hemorrhagic stroke and also have a history of taking Xarelto. Lawyers are investigating these inquiries for possible Xarelto lawsuits. The Onder Law Firm is renowned for its achievements in product and consumer safety litigation, with a strong track record of winning meaningful settlements for clients. The firm is nationally-renowned for its work on window blind strangulation, and has notable expertise in fighting on behalf of individuals against powerful corporations. Individuals and the family members of individuals who have suffered from internal bleeding and have taken Xarelto are eligible for a no-cost, no-obligation Xarelto lawsuit case review, and may contact the firm through its Xarelto Contingency Lawsuit website. The firm provides information on bleeding warnings and Xarelto lawsuit news.
The Onder Law Firm also welcomes Xarelto lawsuit inquiries from other law firms, either to handle these inquiries or work as co-counsel.
http://www.bio-medicine.org/medicine-news-1/Xarelto-Lawsuit-News-3A-Bellwether-Trials--Wrongful-Death-Allegations-149346-1/

Return to headline | Return to top
Xarelto Lawsuit Update: Statute of Limitations Expiring on Potential Lawsuits

Sep 29, 2015 | Digital Journal

By Marc Goldich

BloodThinnerHelp.com reports today on the statutes of limitations for Xarelto lawsuits and how they vary over different states. The statutes of limitations are a set of laws on the books that dictate the amount of time that a plaintiff has to bring a lawsuit forward. The time period usually begins when the event occurred or should have been discovered. If the plaintiff does not bring a lawsuit forward within this time period, they will be permanently barred from recouping damages. It is very important to file a Xarelto lawsuit as soon as you can to make sure that the statute of limitations does not expire on your case.
Since the statute of limitations vary from state to state for the Xarelto lawsuits, we have listed the statutes of limitations concerning defective products cases for several states below:
Defective Product Lawsuits in Pennsylvania – 2 years from date of injury
Defective Product Lawsuits in New Jersey – 2 years from date of injury
Defective Product Lawsuits in California – 2 years from date of injury
Defective Product Lawsuits in New York – 3 years from date of injury
Defective Product Lawsuits in Washington D.C. – 3 years from date of injury
Xarelto Internal Bleeding Lawsuits Filed Across Country:
To this date, there have been more than 1,200 federally filed lawsuits against the manufacturers against Xarelto. These lawsuits commonly allege that Xarelto causes severe, uncontrollable internal bleeding and that the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson, failed to adequately warn doctors and patients about the true dangers of the blood thinner. These federally filed lawsuits have since been consolidated into a multidistrict litigation, MDL, in the Eastern District of Louisiana. There are also about 400 lawsuits filed in a Mass Tort Group in Philadelphia.
The Dangers of Xarelto:
Xarelto is much more dangerous than other blood thinners on the market because it does not have a corresponding antidote, meaning there is no way to counteract the anticoagulant effects of Xarelto in the event of an emergency. For example, if a patient is taking the traditional blood thinner Warfarin and experiences an internal bleeding emergency, a doctor can administer Vitamin K to the patient and their blood will clot again. If the patient is taking Xarelto and experiences an internal bleed, there is no way to stop the bleeding and the situation can become very serious very quickly.
“If you or a loved one believe that you have been harmed by Xarelto, we urge you to contact us immediately.” Xarelto attorney Marc Goldich said, “Do not let the statute of limitations expire on your case before you can get justice.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.

http://www.digitaljournal.com/pr/2688664

Return to headline | Return to top
Xarelto Lawsuit News: New Xarelto Settlement Update

Sep 29, 2015 | WDRB.com

By Marc Goldich

September 29, 2015 – /PressAdvantage/ – BloodThinnerHelp.com reports today on the latest news about Xarelto lawsuit settlements. Although at this point in time no settlements have been made, initial trial dates have been announced and the litigation is moving forward.
The lawsuits that are filed in the Xarelto multidistrict litigation, MDL, all make similar allegations against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals, including that the drug can cause severe uncontrollable internal bleeding and that the manufacturers were aware of the dangers of Xarelto and failed to adequately warn doctors and patients about them. Because the cases against Xarelto are filed as individual personal injury lawsuits, it is very difficult to say how much these cases will settle for since the circumstances of each case are very different.
Initial Xarelto Trials Announced:
Although there have been no settlements on the Xarelto litigation yet, the dates for the bellwether trials have been set. The Xarelto trials will begin on February 6, 2017 in the Eastern District of Louisiana. A second trial will take place in the same district on March 13, 2017, a third trial will occur in Mississippi on April 24, 2017, and a fourth will be held in Texas on May 30, 2017.
The lawsuits filed all contain different types of damages, some economic and some non-economic. Economic damages consist of medical expenses, long term and future medical care, loss of earnings, loss of future income, and funeral and burial expenses. Non-economic damages consist of compensation for pain and suffering and for loss of companionship. Each case will have varying amounts of these damages listed, which is what makes estimating a settlement very difficult.
To make a rough estimate, we can look to a case in recent history that is similar to Xarelto. In May 2014 Pradaxa, a blood thinner that is similar to Xarelto, settled cases that were similar in nature to the Xarelto litigation that is currently unfolding. Pradaxa’s manufacturers, Boehringer Ingelheim, settled 4,000 lawsuits against their blood thinner for $650 million dollars.
“We are still unsure how the Xarelto litigation will play out, but we are dedicated to bringing Xarelto victims justice.” Xarelto attorney Marc Goldich said, “We strongly encourage anybody who has been harmed by Xarelto to contact us immediately.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.wdrb.com/story/30144613/xarelto-lawsuit-news-new-xarelto-settlement-update

Return to headline | Return to top
Xarelto MDL Lawsuits Are Different From Class Actions

Oct 1, 2015 | KUSI News

By Marc Goldich

October 01, 2015 – /PressAdvantage/ – BloodThinnerHelp.com reports today on the difference between the current Xarelto litigation and class action lawsuits. Although sometimes confused or used interchangeably, multidistrict litigation and class action lawsuits are very different. A large number of the current cases filed against the manufacturers of Xarelto, more than 1,200, are consolidated into a federal multidistrict litigation in the United States District Court for the Eastern District of Louisiana. Consolidating cases into an MDL still allows these cases to be tried separately and settlements to be decided individually. This is especially important because the circumstances of the cases filed and the injuries the plaintiffs suffered all greatly vary. For more detailed information on the Xarelto lawsuits, click here.
In a class action lawsuit, all of the cases filed are consolidated into one large case and the result will be the same for everyone involved, making it very inappropriate for the current Xarelto litigation. Currently, there is no class action lawsuit filed against the manufacturers of Xarelto in regards to the drug’s defects.
Xarelto Lawsuits Filed in an MDL:
An MDL is a legal management system that streamlines the judicial process for all parties involved. In December 2014 a motion was filed to consolidate all of the federally filed Xarelto lawsuits into an MDL. Lawsuits can be filed into an MDL if they all make similar allegations against the same defendant. An MDL enables thousands of cases to move quickly through the legal system, saves on judicial resources, and speeds up the process for both sides. In addition to the Xarelto MDL, there are about 400 cases filed in a mass tort group in Philadelphia, a similar legal management system.
Xarelto Lawsuits Make Similar Allegations:
The Xarelto lawsuits are able to be consolidated because they make similar allegations against the drug, including that the drug causes severe internal bleeding which can lead to serious injury and death. The lawsuits also allege that the manufacturers of Xarelto, Bayer AG and Johnson&Johnson, were aware of the dangers of the drug yet released it onto the market anyway.
The lawsuits allege that Xarelto is a more dangerous drug than traditional blood thinners because Xarelto does not have a corresponding antidote. If a patient experiences an internal bleeding injury and is taking a traditional blood thinner such as Warfarin, a doctor will be able to administer Vitamin K and the patient’s blood will clot again. If a ptient is taking Xarelto and suffers an internal bleed, there is no drug available to reverse Xarelto’s anticoagulant effects and make their blood clot.
“We strongly encourage anyone who believes they have been harmed by Xarelto to contact us immediately.” Marc Goldich, Xarelto attorney, said. “We expect to see more cases filed as the litigation progresses.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.kusi.com/story/30166283/xarelto-mdl-lawsuits-are-different-from-class-actions

Return to headline | Return to top
Xarelto MDL Lawsuits Are Different From Class Actions

Oct 1, 2015 | KCEN-TV

By Marc Goldich

October 01, 2015 – /PressAdvantage/ – BloodThinnerHelp.com reports today on the difference between the current Xarelto litigation and class action lawsuits. Although sometimes confused or used interchangeably, multidistrict litigation and class action lawsuits are very different. A large number of the current cases filed against the manufacturers of Xarelto, more than 1,200, are consolidated into a federal multidistrict litigation in the United States District Court for the Eastern District of Louisiana. Consolidating cases into an MDL still allows these cases to be tried separately and settlements to be decided individually. This is especially important because the circumstances of the cases filed and the injuries the plaintiffs suffered all greatly vary.
In a class action lawsuit, all of the cases filed are consolidated into one large case and the result will be the same for everyone involved, making it very inappropriate for the current Xarelto litigation. Currently, there is no class action lawsuit filed against the manufacturers of Xarelto in regards to the drug’s defects.
Xarelto Lawsuits Filed in an MDL:
An MDL is a legal management system that streamlines the judicial process for all parties involved. In December 2014 a motion was filed to consolidate all of the federally filed Xarelto lawsuits into an MDL. Lawsuits can be filed into an MDL if they all make similar allegations against the same defendant. An MDL enables thousands of cases to move quickly through the legal system, saves on judicial resources, and speeds up the process for both sides. In addition to the Xarelto MDL, there are about 400 cases filed in a mass tort group in Philadelphia, a similar legal management system.
Xarelto Lawsuits Make Similar Allegations:
The Xarelto lawsuits are able to be consolidated because they make similar allegations against the drug, including that the drug causes severe internal bleeding which can lead to serious injury and death. The lawsuits also allege that the manufacturers of Xarelto, Bayer AG and Johnson&Johnson, were aware of the dangers of the drug yet released it onto the market anyway.
The lawsuits allege that Xarelto is a more dangerous drug than traditional blood thinners because Xarelto does not have a corresponding antidote. If a patient experiences an internal bleeding injury and is taking a traditional blood thinner such as Warfarin, a doctor will be able to administer Vitamin K and the patient’s blood will clot again. If a ptient is taking Xarelto and suffers an internal bleed, there is no drug available to reverse Xarelto’s anticoagulant effects and make their blood clot.
“We strongly encourage anyone who believes they have been harmed by Xarelto to contact us immediately.” Marc Goldich, Xarelto attorney, said. “We expect to see more cases filed as the litigation progresses.”
For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://www.kcentv.com/story/30166283/xarelto-mdl-lawsuits-are-different-from-class-actions

Return to headline | Return to top

Plaintiff Attorney Blog Posts

Florida Widow Claims Xarelto Injury Caused Husband’s Death

Sep 25, 2015 | Top Class Actions

By Tamara Burns

A Florida widow has filed a dangerous drug lawsuit against the maker of Xarelto, claiming the blood thinning drug caused the wrongful death of her husband.
Plaintiff Betty H., the widow of Ronald H., filed the Xarelto lawsuit against Janssen Pharmaceuticals, its parent company Johnson & Johnson and affiliated companies over the alleged injury caused by her late husband Ronald’s Xarelto usage.
Ronald began taking Xarelto in November 2012 through January 2013. In January 2013, Ronald suffered from severe gastrointestinal bleeding attributed to Xarelto use.
He was hospitalized and had a number of surgeries and procedures for two months. Ronald’s bleeding incident turned fatal and he entered hospice care and died in May 2013.
Betty is suing both for personal injury to her husband as well as related loss of consortium. She brings forth eight counts against the defendants, including negligence, fraudulent misrepresentation, and negligent failure to issue a timely post-sale warning. She has demanded a jury trial for this case.
Additionally, the Xarelto lawsuit is a tag-along action to the Xarelto MDL currently pending under District Court Judge Eldon E. Fallon in the U.S. District Court in New Orleans.
What is Xarelto?
Xarelto is an anticoagulant used to prevent blood clots in patients who are at risk. The drug was FDA approved in July 2011 for prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE) for patients who were undergoing hip or knee replacement surgeries.
In November of the same year, it was also approved to reduce stroke risk and systemic embolism in patients with non-valvular atrial fibrillation.
Xarelto is considered a new generation anticoagulant medication. For many years, the only blood thinning anticoagulant in wide use was warfarin. Warfarin performed well in patients, but did require a lot of monitoring by the physician and patients had to maintain certain dietary restrictions while taking the drug.
Xarelto and other recently developed anticoagulants seemed to be a great addition to allow physicians to administer a medication that did not have the special considerations that warfarin had, thus simplifying patient care.
Complications of Xarelto Use
The most common and most severe complication of Xarelto use is severe internal bleeding. Because Xarelto causes the blood to thin, the natural clotting mechanism to stop bleeds is disrupted and is essentially overridden. Internal bleeds can occur in number of locations in the body, such as in the lungs, gastrointestinal organs, inside the brain or elsewhere.
Warfarin also had bleeding as a known complication of use. However, warfarin had a reversal agent to stop bleeding from progressing once it began. Fresh frozen plasma and vitamin K were used as an antidote to curtail the bleeding.
Xarelto has no antidote, so it is not possible to effectively stop a bleed once it starts. Prolonged Xarelto bleeding can cause severe organ damage, and as in Betty’s husband’s case, it can also be fatal.
Xarelto Lawsuit Information
If you or a loved one has suffered from gastrointestinal bleeding, pulmonary bleeding, intracranial bleeding or other bleeding or if a loved one has died from use of Xarelto, you may be entitled to legal compensation.
While no Xarelto class action lawsuit litigation is available, individuals my join a multidistrict litigation or file a Xarelto lawsuit individually. A confidential consultation with a Xarelto lawyer can help you decide your best course of action.
The Xarelto Lawsuit is Case No. 2:15-cv-01676-EEF-MBN and is part of the Xarelto MDL No. 2529 In Re: Xarelto (Rivaroxaban) Products Liability Litigation, Case No. 2:14-md-02592, in the U. S. District Court for the Eastern District of Louisiana in New Orleans.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/160705-florida-widow-claims-xarelto-injury-caused-husbands-death/

Return to headline | Return to top
Japan Expands Indication For Blood Thinner Xarelto

Sep 28, 2015 | Righting Injustice

By Jennifer Walker-Journey

The controversial blood thinner Xarelto has been granted clearance by Japanese drug regulators for expansion of the drug’s usage to include the treatment and secondary prevention ofpulmonary thromboembolism (PE) and deep vein thrombosis (DVT).
DVT is a condition in which blood clots form in one of the large, deep veins, generally in the legs. PE is a condition that occurs when a blood clot travels to the lungs and partially or completely block a branch of a pulmonary artery. PE can be fatal if the blood clot is large, there are multiple clots, or if the patient has heart or lung disease. PE and DVT, collectively, are known as venous thromboembolism, and are the third most common cardiovascular disorder.
Xarelto, manufactured by Bayer and Johnson & Johnson’s unit Janssen Pharmaceuticals, is also approved in Japan for the prevention of strokes in patients with a heart condition known as atrial fibrillation, and for the prevention of blood clots in patients who have recently undergone hip or knee replacement surgery.
Xarelto was approved by the U.S. Food and Drug Administration (FDA) in 2012, and is used as a treatment for the same conditions. It is designed to be a more convenient alternative to the long-used warfarin, which requires patients to be monitored on a regular basis.
Both drug carry warnings for major bleeding events, including gastrointestinal bleeds, brain hemorrhages and bleeding deaths. In many cases, patients taking warfarin who experience an uncontrolled bleed can be given vitamin K that can reverse the blood thinning qualities of the drug. There is no reversal agent currently available for Xarelto.
Bayer and Janssen currently face hundreds of lawsuits alleging the companies did not thoroughly vet the drug before seeking FDA approval, and failed to adequately warn patients or their doctors of the bleeding side effects associated with Xarelto.
http://www.rightinginjustice.com/news/2015/09/28/japan-expands-indication-for-blood-thinner-xarelto/

Return to headline | Return to top
Xarelto Bellwether Trials Set to Begin in 2017

Sep 29, 2015 | Childress, Schlueter & Smith

A series of Xarelto bellwether trials may begin as soon as February 2017, according to a Case Management Order issued on September 17 by the U.S. District Court, Easter District of Louisiana.
The cases are part of a federal multidistrict litigation (MDL) established in December 2014 to consolidate product liability complaints filed in federal court involving bleeding problems with the anticoagulant drug Xarelto. Early bellwether trials are commonly conducted to further the efficient progress of litigation.
Although the outcomes of these trials will not specifically be binding upon other lawsuits, these cases will be tried to help the parties gauge how juries might respond to certain evidence and testimony that will likely be presented throughout the litigation. Pursuant to the Order, the first two trials will take place in the Eastern District of Louisiana in February and March 2017, and the others to follow in Mississippi in April and Texas in May, districts to be determined.
Xarelto Benefits and Risks
Xarelto was approved by the U.S. Food and Drug Administration (FDA) in November 2011 to reduce the risk of stroke and blood clots associated with non-valvular atrial fibrillation, to treat deep vein thrombosis (DVT) and pulmonary embolism (PE), and to reduce the risk of DVT and PE in patients undergoing knee or hip replacement surgery. It works by inhibiting the enzyme in the blood that causes it to clot, but with no approved antidote available that will quickly reduce Xarelto’s blood thinning effects, serious and even fatal bleeding events have occurred among the medication’s users.
Xarelto Lawsuit Allegations
The Xarelto lawsuits all involve similar allegations: the failure on the part of the drug’s makers, Janssen Research and Development and Bayer Healthcare Pharmaceuticals, to provide adequate warnings about the potential side effects of Xarelto, which include irreversible brain and gastrointestinal bleeding and uncontrollable hemorrhaging.
Similar to other anticoagulants, the Xarelto label contains warnings about the medication’s potential risk of bleeding events, but the lawsuits allege that the information provided is insufficient and fails to convey the serious and potentially deadly nature of the medication’s side effects.
If you or a loved one has suffered serious, uncontrollable bleeding while on Xarelto, you should speak with Childers, Schlueter & Smith today about seeking compensation. Led by firm partner Andy Childers, our Xarelto injury lawyers can help you understand your legal rights and seek redress for your injuries. It may be the only way to alleviate the financial hardship that has been placed upon you.
http://www.cssfirm.com/2015/09/29/xarelto-bellwether-trials-set-to-begin-in-2017/

Return to headline | Return to top
Xarelto: Higher Risk Same Reward?

Sep 29, 2015 | Lopez McHugh LLP

Over 1,200 Xarelto lawsuits are pending in a multidistrict litigation in the U.S. District Court for the Eastern District of Louisiana. Xarelto plaintiffs allege that the anticoagulant drug’s manufacturers, including Bayer HealthCare Pharmaceuticals and Johnson & Johnson’s Janssen Pharmaceutical, did not provide patients and doctors with adequate warning about Xarelto’s severe bleeding risks.
Approved by the U.S. Food and Drug Administration (FDA) in 2011 to help treat certain patients at risk for embolic events, one of Xarelto’s primary selling points has been its reported reduced risk of severe bleeding. Bayer and Janssen have touted Xarelto as a safer, more effective alternative to Warfarin, the decades-old oral anticoagulant treatment. But mounting evidence suggests Xarelto may be less safe than previously thought.
Medical experts have questioned the legitimacy of Xarelto’s entire approval process, citing violations at clinical trial sites. One of the drug’s premarket studies was so problematic that the FDA refused to factor its results into Xarelto’s approval process. Additionally, the Institute for Safe Medication Practices has noted a consistent upsurge in the number of serious adverse event reports concerning Xarelto, with over 3,000 filed during the last reporting period. More recently, a study by French scientists concluded that Xarelto may be no safer than Warfarin in terms of severe bleeding in elderly patients.
Patients who have filed Xarelto bleeding lawsuits also point out that Xarelto has no approved antidote in case of severe bleeding. Compare this with Warfarin, for which vitamin K infusions can be used in the event of bleeding. This lack of a reliable remedy combined with dubious advantages over Warfarin have placed Xarelto in the middle of a fast-growing multidistrict litigation.
Talk to your doctor about any health risks your medications may pose. If you or a loved one suffered severe bleeding after taking Xarelto, contact Lopez McHugh to discuss your case free of charge with a qualified Xarelto attorney. We can help determine whether a Xarelto lawsuit is right for you.
http://lopezmchugh.com/2015/09/29/xarelto-higher-risk-reward/index.html

Return to headline | Return to top
Xarelto Lawsuit Update: New Pre-Trial Orders Issued in MDL

Sep 30, 2015 | The Legal Herald

By Marc Goldich

Xarelto Lawsuit Update: New Pretrial Orders
Two new pretrial orders were issued in late September for the Xarelto MDL. If you or a loved one have been injured by Xarelto, contact us immediately. BloodThinnerHelp.com reports today on two new orders issued for the Xarelto multidistrict litigation. On September 17, 2015, the United States District Court in the Eastern District of Louisiana, where the MDL is consolidated, issued the second Case Management Order, the full text of which can be found here. The court also issued Pretrial Order 15A, which was an order in regards to the preservation of emails, text messages, and instant messages. Pretrial Order 21 was also issued which established document production protocol for the litigation. More information on the two Pretrial Orders can be found here. For more detailed information on the Xarelto lawsuits, visit this page.
Xarelto Lawsuits Consolidated in MDL
The Xarelto MDL was formed in December 2014 after a motion was made to consolidate the rising number of cases against the manufacturers of Xarelto, Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson. These cases were able to be consolidated because they all made similar allegations against the same defendants, specifically that Xarelto causes serious uncontrollable internal bleeding events which lead to severe injuries and that the manufacturers of Xarelto were aware of the dangers of the drug and failed to adequately warn both doctors and patients about these dangers. Xarelto was initially released onto the United States market in 2011 after approval from the Food and Drug Administration, (FDA) to treat atrial fibrillation, deep vein thrombosis, and to be used in patients who have undergone hip and knee replacement surgeries. The manufacturers heavily marketed Xarelto as a convenient alternative to the traditional blood thinner Warfarin, stating that Xarelto users did not need frequent blood monitoring and did not have to follow a strict diet that Warfarin requires. Advertisements for the drug could be found in magazines, on television with commercials starring well known athletes and public figures, and also in highly respected medical journals. Xarelto sales skyrocketed in the initial months. Despite these conveniences, the lawsuits allege that Xarelto is a much more dangerous drug than other blood thinners on the market.
Xarelto's Serious Side Effects
Xarelto works differently than traditional blood thinners because it blocks the chemical in the blood that is responsible for making the blood clot, thrombin. By blocking thrombin, Xarelto competently takes away the blood's ability to clot on its own. This is dangerous because there is no antidote for the effects of Xarelto, meaning that in the event of an internal bleeding emergency, there is no way to reverse the drug's anticoagulant effects. The lack of antidote has led to Xarelto users experiencing uncontrollable internal bleeding, which can lead to even more serious injuries and even death. "We strongly urge anyone who has been harmed by Xarelto to contact us immediately." Xarelto attorney Marc Goldich said, "Now that the Xarelto litigation is moving forward, we expect to see even more cases filed in the MDL." For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.
http://legalherald.com/xarelto-lawsuit-update-new-pre-trial-orders-issued-in-mdl/

Return to headline | Return to top
Fair Rate Funding Now Offering Lawsuit Funding for Xarelto Lawsuits

Sep 30, 2015 | Fair Rate Funding

Xarelto (rivaroxaban) is an anticoagulant (blood thinner) that prevents the formation of blood clots and is marketed by Johnson & Johnson and manufactured by Bayer. Its primary use is to reduce the risk of blood clots in the legs and lungs of people who recently had a hip or knee replacement surgery. It is also used to treat and reduce the risk of deep vein thrombosis, pulmonary embolisms and strokes.
Uncontrollable bleeding is the most dangerous risk associated with blood thinners. Other serious injury risks include bleeding in the intestines, rectal bleeding, brain hemorrhage and death.
The Institute for Safe Medication Practices revealed that blood thinners – including Xarelto – were the most dangerous drugs with the highest number of serious side effects reported to the FDA.http://www.drugwatch.com/xarelto/lawsuit/. Many patients and their physicians are concerned that Xarelto will cause the same serious bleeding complications as Pradaxa.
The complications are serious. Reports of dangerous blood clots are already being reported to the FDA by people who are or have taken the drug Xarelto. Some injuries that are currently being reported are:Death caused by uncontrollable bleedingIntestinal bleedingRectal bleedingBrain hemorrhaging
A large number of lawsuits are now being filed against the manufactures (Bayer and Janssen Pharmaceuticals) that the defendant manufacturers concealed important safety information from the public and did not thoroughly test the medication before it was place for consumption in the marketplace.
Ultimately, the Xarelto lawsuit cases may be consolidated into a multi-district-litigation (MDL). When large numbers of plaintiffs file against only a few defendants, consolidation of cases can help simplify the litigation process because judges who are familiar with the facts can adjudicate the cases more efficiently. Plaintiffs will still keep their attorneys, but the cases are handled as a group for logistical reasons.
Because these lawsuits often require expert testimony to prove damages, the discovery process can often drag on for years. While this is going on, plaintiffs often encounter severe emotional and financial stress. This condition can be improved with some extra money. A lawsuit cash advance from Fair Rate Funding can help.
If you have a lawsuit based on damages caused by Xarelto and need Xarelto lawsuit funding or lawsuit funding in connection with any defective drug lawsuit, and have a lawyer representing you on a contingent fee basis (he/she only gets paid when you win your lawsuit) you may eligible for Xarelto lawsuit funding from Fair Rate Funding. If you are in the need of immediate cash while waiting for compensation on your case, Fair Rate Funding can provide a Xarelto lawsuit cash advance funding to help pay for your expenses while your case is being litigated.
We know you have a choice of Xarelto lawsuit funding companies and are happy to assist you in your time of need. To obtain a lawsuit loan in the quickest and easiest manner, please fill out the submission form on this page. One of our agents will contact you immediately and start the process. You can then simply sit back and allow Fair Rate Funding to do its job. We regularly process and provide lawsuit cash advances within 24 hours of receiving the paperwork from your attorney.
We provide Xarelto lawsuit funding in the following states: Alabama, Alaska, Arizona, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Texas, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, Wyoming and the District of Columbia D.C.
*Call Fair Rate Funding for details on what types of pharmaceutical cases are eligible for Xarelto lawsuit cash advance funding.
Thank you for choosing Fair Rate Funding.
http://www.fairratefunding.com/xarelto-lawsuits/sample-data-articles/xarelto-lawsuit-funding

Return to headline | Return to top
Plaintiffs Claim Xarelto Is Unsafe and Improperly Marketed

Sep 30, 2015 | LawyersandSettlements.com

By Gordon Gibb

New Orleans, LA: A Xarelto Lawsuit filed this past March raises a lot of the same questions other plaintiffs have been raising with regard to Xarelto Bleeding complications that can’t be stopped as easily as similar bleedouts associated with use of the much older Coumadin (warfarin).

The latter is a heritage blood thinner that requires constant monitoring to help prevent unexpected bleeding events - an anticoagulant, however, that has the potential for reversing its blood-thinning properties with an infusion of vitamin K.

Xarelto was released to the market with no such option - and for many, a Xarelto Bleedout has resulted in Xarelto death when a hemorrhage could not be stemmed due to the lack of an antidote. Plaintiffs have maintained they were not aware of this, and would have avoided Xarelto, in spite of its added convenience, in an effort to avoid a potentially catastrophic event.

But now there is a new wrinkle - Xarelto Bleedout lawsuits that allege manufacturers Johnson & Johnson and Janssen Research & Development LLC were negligent in promoting Xarelto as a safe and effective alternative to Coumadin that did not require the same kind of stringent monitoring required of warfarin. Plaintiffs - as well as a growing cacophony in the medical community - are now saying that monitoring is especially important for a product that carries no capacity for reversal, should catastrophic Xarelto Bleeding complications occur.

That’s an accusation contained in a Xarelto lawsuit brought by the son of a Xarelto patient who died an alleged Xarelto Death due to a Xarelto Bleedout that could not be contained. According to court documents, Tommy Julien was prescribed Xarelto to help treat his atrial fibrillation, which put him at risk for stroke. That was in November 2012.

Five months later Julien was back in the hospital with serious internal bleeding, from which he could not recover. He died on March 29, 2013.
Julien’s son Danny Julien has launched a Xarelto Lawsuit alleging failure to warn about the absence of an appropriate reversing agent, and negligence in promoting the safety, efficacy and convenience of a product that in the plaintiff’s view is not safe at all without strict monitoring and the availability of an antidote. Julien states in his Xarelto lawsuit that such deficiencies and failures were undertaken “willfully, intentionally, and with reckless disregard of the life and safety of the Decedent and the general public.”

He seeks in excess of $75,000 in compensatory and punitive damages.

The lawsuit alleging Xarelto Death, Xarelto Bleeding complications and Xarelto Side Effects is one of over a thousand similar cases consolidated in multidistrict litigation before US District Judge Eldon E. Fallon in the Eastern District of Louisiana. The first bellwether lawsuit is expected for August 2016.

The lawsuit is Julien v. Janssen Research & Development LLC et al, Case No. 2:15-cv-00886, filed March 20th, 2015 at Louisiana Eastern District Court.
http://www.lawyersandsettlements.com/articles/xarelto/xarelto-lawsuit-death-bleeding-issue-26-20949.html#.Vg7VxctViko

Return to headline | Return to top
Xarelto Lawsuit (YouTube Video)

Oct 1, 2015 | YouTube

By Ben Jones

The video only features text that discusses the alleged dangers of Xarelto and prompts individuals to contact the law firm for a free consultation.
Video: https://www.youtube.com/watch?v=6_OAUlRxl_0

Return to headline | Return to top
Have You Been Harmed By Xarelto? Here’s How We Can Help

Oct 1, 2015 | Baron Budd

Xarelto, the brand name of the drug rivaroxaban, is a blood thinner marketed as a much more convenient alternative to older medications such as warfarin, which has been in use since the 1950s. Manufactured by Johnson & Johnson subsidiary Janssen Pharmaceuticals, Xarelto has been linked to several serious – and often fatal – health problems caused by uncontrolled bleeding. As a result, people across the country are filing Xarelto lawsuits.
Why Lawsuits are Filed
There are a lot of potential reasons someone would consider filing a Xarelto lawsuit. Some people do so due to financial hardship resulting from their medical problem due to lost wages as well as money spent on emergency medical visits and ongoing care. Others have taken legal action in an effort to obtain compensation for emotional distress or financial expenses caused by the death of a loved one.
Plaintiffs in these cases are making a variety of allegations, including:
Xarelto was marketed as being a superior anti-coagulant despite evidence that showed the drug posed a greater risk of gastrointestinal bleeding than competing medications.
Doctors and patients did not receive proper warning regarding the potential dangers of Xarelto.
Xarelto has been linked to several severe medical conditions, including brain hemorrhages, stomach and eye bleeding, infections and more.
Talk to an Attorney
Complications associated with Xarelto can lead to traumatic, emotional experiences for families. Ever-growing medical bills can ruin finances, and frustration and stress can accumulate to a boiling point. In some instances, the only way to obtain proper compensation for financial losses, pain and suffering is to file a Xarelto lawsuit.
https://baronandbudd.com/protecting-whats-right/2015/09/harmed-by-xarelto/

Return to headline | Return to top
Xarelto Lawsuit Filings Keep Coming

Oct 1, 2015 | Bernstein Liebhard LLP

By Sandy Liebhard

Xarelto lawsuits continue to pile up in courts around the country. Most recently, 12 plaintiffs filed suit in Louisiana federal court accusing Johnson & Johnson and Bayer Corp. of downplaying the risk of internal hemorrhaging associated with the new-generation blood thinner.
According to Law360.com, two of the plaintiffs represent the estates of people who allegedly died due to Xarelto bleeding. All claim that the defendants’ misleading marketing campaigned induced their physicians to prescribe Xarelto instead of safer alternatives.
“The use of Xarelto without appropriate blood monitoring, dose adjustment and twice a day dosing can cause major, life-threatening bleeding events,” the plaintiffs said. “Importantly, Xarelto’s significant risk of severe, and sometimes fatal, internal bleeding has no antidote to reverse its effects.”Xarelto among Fastest Growing Product Liability Litigations
The new filings helped push the number of Xarelto lawsuits now pending in the U.S. District Court, Eastern District of Louisiana above 2,500 cases. According to a report from Reuters, the consolidated litigation currently underway in that jurisdiction is now one of the fastest-growing products liability dockets in the country.
Earlier this month, the Court issued a new Case Management Order indicating that it would convene four bellwether trials starting in February 2017. The first two will take place in the Eastern District of Louisiana, while one each will be venued in yet-to-be-determined districts in Texas and Mississippi. The process of selecting cases for those trials will begin next year.
Xarelto is a new blood thinning medication that was intended to replace warfarin, an anticoagulant that has been on the market for decades. However, there currently exists no approved antidote to reverse Xarelto bleeding side effects. Warfarin can also cause internal bleeding, but such complications can be stopped via the administration of vitamin K.
In the U.S., Xarelto is approved for the prevention of strokes in people with atrial fibrillation; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee replacement surgery. The drug’s label includes a black box warning that contains information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.
Attorneys at Bernstein Liebhard LLP represent Xarelto plaintiffs, and they continue to provide free legal reviews to those who may have been harmed by this drug. To learn more, please call (888) 979-1182.
http://www.thexareltolawsuit.com/xarelto-lawsuit-filings-keep-coming/

Return to headline | Return to top
Xarelto Bleeding Lawsuit Alleges Ohio Man Bled to Death

Oct 2, 2015 | Top Class Actions

By Ashley Vanover

The controversial blood thinning drug Xarelto has been named in yet another lawsuit – this time following the death of an Ohio resident who was prescribed the medication in July 2013.
Plaintiff Judy C., filing on behalf of her deceased spouse, commenced her Xarelto wrongful death lawsuit on Sept. 15 in Louisiana federal court, home of the ongoing Xarelto MDL to address the alleged widespread injuries caused by the new generation anticoagulant.
According to the Xarelto lawsuit, the decedent Jerry C. used Xarelto beginning in July 2013 through September 2013, and subsequently suffered fatal internal bleeding. Jerry ultimately died on Oct. 20, 2013, due to his injuries that were allegedly a direct result of using Xarelto
The Xarelto lawsuit further accuses the defendants of purposely concealing important safety information from the medical community, the U.S. Food and Drug Administration, and the public; the case also claims the pharmaceutical companies did not test the drug enough before it was put on the market.
Xarelto Side Effects
At the heart of the Judy’s Xarelto lawsuit are the allegations that the makers of Xarelto engaged in deceitful marketing practices and failed to disclose known Xarelto bleeding risks and side effects.
The drug Xarelto was approved by the Food and Drug Administration (FDA) in 2011 for the treatment of deep-vein thrombosis and similar clotting risks following knee or hip surgery. Its arrival to the market was initially well-received, as the drug was considered a more-convenient alternative to the long-standing anticoagulant known as warfarin.
Unlike warfarin, however, Xarelto’s aggressive marketing campaigns promised patients they could maintain an active lifestyle without diet restrictions or regular trips to the blood clinic.
What these advertisements failed to mention, according to the Xarelto lawsuit, was that the blood thinner could cause a sharp increase in bleeding risks. This new generation blood thinner has been named in several studies as a dangerous anticoagulant alternative that should be used only under close supervision.
Xarelto Lawsuits
Xarelto has been targeted with increasing scrutiny over the past several years, and its manufacturers are alleged to have unlawfully concealed the truth about its tendency to cause life-threatening hemorrhages and internal bleeding. Consequently, a Xarelto multidistrict litigation was formed to help consolidate the growing number of cases against the makers of Xarelto.
The Xarelto lawsuit is seeking compensatory, economic, and punitive damages for Bayer and Janssen Pharmaceutical’s alleged deceptive and reckless practices in misrepresenting and omitting numerous facts about the dangers of taking Xarelto and causing the death of Jerry in part by their gross negligence. The filed complaint indicates a demand for a jury trial for this case.
http://topclassactions.com/lawsuit-settlements/lawsuit-news/173532-xarelto-bleeding-lawsuit-alleges-ohio-man-bled-to-death/

Return to headline | Return to top
Son Blames Xarelto for Father’s Death, Seeks Punitive Damages

Oct 2, 2015 | The Legal Examiner

By Eric T. Chaffin

In December 2014, the U.S. Judicial Panel on Multidistrict Litigation (JPML) consolidated all federal Xarelto lawsuits into one court in the Eastern District of Louisiana before the Honorable Judge Fallon. Currently, about 400 cases are pending there.
One of the cases recently filed involves a plaintiff who claims the anticoagulant blood caused internal bleeding that led to the death of his father.Plaintiff Claims Xarelto Caused Wrongful Death
The plaintiff, a Georgia resident, is the son of the man who allegedly died because of his ingestion of Xarelto. He’s also the representative of the decedent’s estate. He has filed the Xarelto lawsuit against manufacturers Janssen Pharmaceuticals and parent company Johnson & Johnson, as well as against co-manufacturer Bayer AG.
According to the complaint, the decedent was first prescribed Xarelto in November 2012 for his atrial fibrillation. The FDA approved the drug in 2011 for the treatment of non-atrial fibrillation, to help patients reduce their risk of blood clots and stroke.
The decedent continued to take Xarelto for several months. On March 27, 2013, he suffered serious internal bleeding that led to his death. The plaintiff claims that had his father known about the risks associated with Xarelto, he never would have taken it.
Manufacturers Misinformed Patients About Xarelto
The plaintiff also notes in his case that the defendants told patients in advertisements that they wouldn’t need regular blood monitoring when taking Xarelto, like patients normally do when taking warfarin, the leading anti-coagulant for decades. They also noted that there were no known dietary restrictions with Xarelto, like there are with warfarin.
Such advertisements made Xarelto look like a “one size fits all” drug, the plaintiff states, while failing to provide adequate warnings about the risks. The boxed warming on the drug, for example, did not address the increased risk for serious and fatal bleeding, despite early clinical trials showing that in comparison to warfarin, patients taking Xarelto experienced more gastrointestinal bleeds and needed more transfusions.
Doctors Question Lack of Xarelto Bleeding Antidote
The plaintiff also points to a January/February 2013 ad in the WebMD magazine in which the defendants advertised Xarelto—an ad that resulted in a warning letter from the FDA. The administration stated that the ad was misleading because “it minimizes the risks associated with Xarelto and makes a misleading claim.”
He also references a 2012 Huffington Post article in which prominent cardiologists and other health care professionals questioned the use of Xarelto, noting that the drug had no antidote for a bleeding emergency, as warfarin does. Indeed, patients taking warfarin who experience excessive bleeding can be treated with vitamin K injections to encourage blood to clot again. There is no such treatment for patients taking Xarelto who end up in the same situation, making bleeding events much more serious and potentially deadly.
Defendants Failed to Provide Adequate Warnings
As in other Xarelto lawsuits, this one highlights the fact that the manufacturers didn’t do enough to warn doctors and patient of the potential risks, particularly of the fact that there was no readily available antidote for Xarelto bleeding. “Defendants merely indicated that there was a risk for bleeding and side-stepped the important issue of reversing the effects of Xarelto should a bleed occur,” the plaintiff states in his complaint.
He brings claims for failure to warn, defective design, negligence, negligent design, negligent misrepresentation, breach of warranties, and fraud. He seeks both compensatory and punitive damages.
http://newyork.legalexaminer.com/fda-prescription-drugs/son-blames-xarelto-for-fathers-death-seeks-punitive-damages/

Return to headline | Return to top

Add recipients

Suggested